Cel-Sci Corporation
| AMEX: CVM | Healthcare / Biotechnology / USA |
| 2.25 | -0.2000 | -8.16% | Vol 892.45K | 1Y Perf -12.50% |
| Nov 29th, 2023 16:00 DELAYED |
| BID | 2.25 | ASK | 2.31 | ||
| Open | 2.48 | Previous Close | 2.45 | ||
| Pre-Market | - | After-Market | 2.25 | ||
| - - | - -% |
| Target Price | 14.50 | Analyst Rating | Strong Buy 1.00 | |
| Potential % | 544.44 | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | -/-/-100 | Value Ranking | — - | |
| Insiders Value % 3/6/12 mo. | -/-/-100 | Growth Ranking | ★+ — - | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/-100 | Income Ranking | — - | |
| Price Range Ratio 52W % | 52.84 | Earnings Rating | Sell | |
| Market Cap | 106.34M | Earnings Date | 27th Dec 2023 | |
| Alpha | 0.02 | Standard Deviation | 0.32 | |
| Beta | 1.23 |
Today's Price Range 2.252.64 | 52W Range 1.043.33 | 5 Year PE Ratio Range -8.70-2.30 |
Summary:
Buy
| Technical Indicators: | Neutral |
| Moving Averages: | Strong Buy |
| Performance | |||
|---|---|---|---|
| 1 Week | -4.26% | ||
| 1 Month | 71.76% | ||
| 3 Months | 60.71% | ||
| 6 Months | -4.26% | ||
| 1 Year | -12.50% | ||
| 3 Years | -82.00% | ||
| 5 Years | -31.40% | ||
| 10 Years | -88.89% |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -193.26 | |||
ROE last 12 Months | -94.01 | |||
ROA (5Y Avg) | -33.97 | |||
ROA last 12 Months | -65.56 | |||
ROC (5Y Avg) | - | |||
ROC last 12 Months | -54.07 | |||
Return on invested Capital Q | -18.60 | |||
Return on invested Capital Y | -60.93 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | 0.00 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -2.90 | ||||
| 3.38 | ||||
| - | ||||
| - | ||||
| -7.70 | ||||
| -0.42 | ||||
| 3.40 | ||||
| 0.74 | ||||
| 101.39M | ||||
| Forward PE | -5.25 | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 4.90 | ||||
| 5.50 | ||||
| 0.30 | ||||
| 0.48 | ||||
| -32.90 | ||||
| Leverage Ratio | 1.50 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.00 | ||||
| 0.00 | ||||
| - | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q03 2023 | -0.17 | -0.19 | -11.76 |
| Q02 2023 | - | -0.19 | - |
| Q01 2023 | - | -0.18 | - |
| Q04 2022 | - | -0.21 | - |
| Q03 2022 | -0.15 | -0.23 | -53.33 |
| Q02 2022 | -0.16 | -0.23 | -43.75 |
| Q01 2022 | - | -0.20 | - |
| Q04 2021 | -0.10 | -0.19 | -90.00 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 9/2023 QR | -0.16 | 0.00 | - |
| 9/2023 QR | -0.16 | - | - |
| 9/2023 FY | -0.71 | -2.90 | Negative |
| 9/2024 FY | -0.48 | 0.00 | - |
| Next Report Date | 27th Dec 2023 |
| Estimated EPS Next Report | -0.16 |
| Estimates Count | 1 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 892.45K |
| Shares Outstanding | 47.26K |
| Shares Float | 45.55M |
| Trades Count | 4.97K |
| Dollar Volume | 2.19M |
| Avg. Volume | 952.25K |
| Avg. Weekly Volume | 600.26K |
| Avg. Monthly Volume | 1.06M |
| Avg. Quarterly Volume | 1.19M |
Cel-Sci Corporation (AMEX: CVM) stock closed at 2.25 per share at the end of the most recent trading day (a -8.16% change compared to the prior day closing price) with a volume of 892.45K shares and market capitalization of 106.34M. Is a component of indices and it is traded on AMEX exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 0 people. Cel-Sci Corporation CEO is Geert R. Kersten.
The one-year performance of Cel-Sci Corporation stock is -12.5%, while year-to-date (YTD) performance is -4.26%. CVM stock has a five-year performance of -31.4%. Its 52-week range is between 1.04 and 3.3299, which gives CVM stock a 52-week price range ratio of 52.84%
Cel-Sci Corporation currently has a PE ratio of -2.90, a price-to-book (PB) ratio of 3.38, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -65.56%, a ROC of -54.07% and a ROE of -94.01%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from Cel-Sci Corporation, there were 0 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.16 for the next earnings report. Cel-Sci Corporation’s next earnings report date is 27th Dec 2023.
The consensus rating of Wall Street analysts for Cel-Sci Corporation is Strong Buy (1), with a target price of $14.5, which is +544.44% compared to the current price. The earnings rating for Cel-Sci Corporation stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Cel-Sci Corporation has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Cel-Sci Corporation has a Buy technical analysis rating based on Technical Indicators (ADX : 25.01, ATR14 : 0.28, CCI20 : 68.53, Chaikin Money Flow : 0.24, MACD : 0.27, Money Flow Index : 50.90, ROC : -3.92, RSI : 58.40, STOCH (14,3) : 42.38, STOCH RSI : 0.32, UO : 54.34, Williams %R : -57.62), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Cel-Sci Corporation in the last 12-months were:
Cel-Sci Corporation
CEL-SCI Corp is a player in the biotechnology sector. It is engaged in the research and development at developing the treatment of cancer and other diseases by using the immune system. The company is focused on activating the immune system to fight cancer and infectious diseases. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), investigational immunotherapy under development for the treatment of certain head and neck cancers, and anal warts or cervical dysplasia.
CEO: Geert R. Kersten
Telephone: +1 703 506-9460
Address: 8229 Boone Boulevard, Vienna 22182, VA, US
Number of employees: 0
